Highly sensitive, rapid and non-invasive speckle-tracking-based echocardiographic imaging & enhanced analysis for cardiovascular studies.
VevoStrain™ software is a sensitive tool for assessing myocardial performance and showcasing changes in regional & global heart motion post-infarct or in response to therapeutic agents. The software is optimized for small animal heart imaging.
|
 |
|
|
| a) | b) | |
| Vector velocity tracking in (a) normal and (b) infarct mouse heart model with VevoStrain software. | ||
- Post-processing quantification of myocardial wall abnormalities in circumferential, radial and longitudinal axes of heart motion
- Data quantification exportable in .csv format
- Quantitative analysis by vector and parametric displays
What is Speckle-Tracking?
Speckle-tracking echocardiography (STE) is a novel method for determining strain and strain rate. The tracking system is based on the distance measurement between 2 stable patterns, or “speckles” on a 2D or 3D echocardiographic image of a left ventricular heart segment during the cardiac cycle. Unlike Doppler-derived strain imaging, STE is angle-independent, thereby minimizing variabilities in the quantification of regional and global LV function.
 |
 |
 |
||
| Speckle-tracking echocardiography is based on normal ventricular function, in which myocardial deformation occurs along the longitudinal, radial and circumferential axes. | ||||
VevoStrain software, is a new quantification tool available with the Vevo 2100 which uses B-Mode speckle-tracking analysis to track wall motion abnormalities. This tool provides both regional and global wall motion tracking, offering quantification of the velocity of the walls, displacement, strain, strain rate and time to peak analysis..
VevoStrain Software for Cardiac Strain Analysis
Strain is a valuable tool in cardiovascular disease, cardiac regeneration, cancer therapeutics, and broader drug development areas. It can be used to sensitively monitor cardiac function and ventricular remodeling for early signs of cardiotoxicity in patients or animal models under anti-cancer therapies (Jurcut et al, 2008). Given their ease of use, high reproducibility, and flexibility, it is no wonder that strain and strain rate are already being hailed as essential tools in the repertoire of any researcher interested in cardiac function.
Heart Failure in a Mouse Model
 |
 |
|
| a) | b) | |
| Parametric display of a (a) normal and (b) heart failure mouse model displayed for 48 heart parameter points. Synchronous velocity can be seen in the healthy mouse heart, while dyssynchrony is present in the infarct heart. | ||
High-sensitivity, in vivo assessment of cardiac function has emerged as an essential new method for evaluating novel therapies and molecular applications in small animal models of cardiovascular disease. VevoStrain software is powerful analysis tool that offers researchers the ability to assess:
- Regional & global wall motion tracking
- Measurements of displacement, velocity, strain and strain rate
- Left ventricular function quantification across both long and short axes
3D parametric display of strain and strain rate with the VevoStrain software.
Research Study:
In comparison to current, conventional echocardiographic measurement methods, VevoStrain speckle-tracking based measures have been found to:
- Have greater sensitivity for detecting global changes in cardiac function after myocardial infarct
- Allow region-specific functional assessments in infarcted vs. non-infarcted myocardial areas
- Identify response to standard cardiac therapy as early as 3 weeks post-myocardial infarction
Bauer et al., “Echocardiographic Speckle-Tracking Based Strain Imaging for Rapid Cardiovascular Phenotyping in Mice.” Circulation Research. April 2011.
It’s easy to obtain high quality, reproducible data quickly:
- Capture small animal cardiac images in 2D
- Apply VevoStrain software to acquired data to assess myocardial performance
Jurcut R, Wildiers H, Ganame J, et al. Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Support Care Cancer 2008 May;16(5):437-45
